A handshake price on the family cabin feels like a generous shortcut, but the IRS sees two deals on that dock. One of them could cost his kids hundreds of thousands in tax on…
ServiceNow's revenue keeps climbing, yet its shares dropped 30% in a single week after earnings. A five-year model sketches three paths for the stock, and one of them looks a lot different from what…
Rocket Lab posted a record backlog and still got punished, while rivals that depend on the same scarce rockets slid too. One bottleneck links three stocks, and it explains which part of the earnings…
A late-night report promised a $26 billion supplier stampede into Anthropic's IPO, then Anthropic called its own pricing inaccurate. Only one commitment appears in an SEC filing, so which backer holds the real stake?
The Nasdaq hides some of the market's fattest paychecks, but one of them has slashed its payout before and just posted a $1.36 billion loss. Which of these three income plays can actually cover…
Fifty years of dividend raises sounds bulletproof, yet several former Kings broke their streaks. We checked earnings and cash flow behind four of the highest yielders, and one payout looks far shakier than the…
A 25% after-hours surge vanished before the opening bell, even though The Trade Desk beat on earnings and revenue. One CFO comment about the next two quarters may explain why traders rushed for the…
Wall Street sees a price target far above Broadcom's all-time high, even as AI chip sales triple and the stock lags the market. One December report could reveal whether sentiment or the business is…
Digital Turbine beat on sales and raised its revenue target, yet investors still rushed for the exits. Behind the headline growth sit a shrinking margin, a cost restatement, and a profit forecast that refused…
The IRS treats most REIT dividends differently from the qualified dividends on ordinary stocks, and that quirk quietly drains thousands from income investors every year. One of five popular payers does the most damage,…
Biotech usually torches cash and dilutes shareholders to fund the next trial. Three drugmakers flip that script, and the one with the smallest yield may be hiding the sturdiest payout of all. Coverage, not…
Intel's 18A chips work, its Xeon business is booming, and TSMC is bleeding margin on 2nm. So why does the market still refuse to pay for Intel's roadmap? One missing signature may decide who…
Rocket Lab's record backlog and billions in cash collide with a delayed rocket, heavy dilution, and shrinking margins. Analysts still see enormous upside, but one test flight in 2027 could decide whether their optimism…
Amazon's cloud arm just posted its fastest growth in nearly five years, yet a spending spree is draining cash at a startling pace. Can the profit engine outrun the bill, and why does one…
Qualcomm's handset business is shrinking fast, yet a quieter segment just posted a record quarter that few investors are watching. Can it outrun the earnings damage, and where does our model say the stock…